NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
19 hedge funds and large institutions have $177K invested in NeuBase Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
14% less funds holding
Funds holding: 22 → 19 (-3)
48% less capital invested
Capital invested by funds: $340K → $177K (-$163K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$23.7K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$947 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$94 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$46.7K |
| 2 |
Two Sigma Investments
New York
|
-$15.6K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$12.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$111 |
| 5 |
BlackRock
New York
|
-$62 |
NBSE Hedge Fund Activity: Q1 2024 in Review
19 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2024, worth a combined $177K — down 48% from $340K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NBSE and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $23.7K. The largest seller was UBS Group, cutting an estimated $46.7K.
- 19 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $177K of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2024, down 48% quarter-over-quarter.
- 2 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2024 and 4 closed out, a net change of -2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2024 was Renaissance Technologies, an estimated $23.7K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2024 was UBS Group, an estimated $46.7K sold.
Based on aggregated 13F filings for Q1 2024.